The Bull Case For MannKind (MNKD) Could Change Following FDA-Backed Afrezza Dosing Label Update

Simply Wall St.

Jan 31

MannKind Corporation recently received FDA approval for an update to Afrezza’s Prescribing Information, refining recommended starting mealtime doses when adults switch from injected or pump-based ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2607078110"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2607078110\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2607078110?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-01-31 04:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2607078110","market":"us","top_or_hot":-1,"title":"The Bull Case For MannKind (MNKD) Could Change Following FDA-Backed Afrezza Dosing Label Update","media":"Simply Wall St.","content":"<div>\n<p>MannKind Corporation recently received FDA approval for an update to Afrezza’s Prescribing Information, refining recommended starting mealtime doses when adults switch from injected or pump-based ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mnkd/mannkind/news/the-bull-case-for-mannkind-mnkd-could-change-following-fda-b\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Bull Case For MannKind (MNKD) Could Change Following FDA-Backed Afrezza Dosing Label Update</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Bull Case For MannKind (MNKD) Could Change Following FDA-Backed Afrezza Dosing Label Update\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-31 04:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mnkd/mannkind/news/the-bull-case-for-mannkind-mnkd-could-change-following-fda-b><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>MannKind Corporation recently received FDA approval for an update to Afrezza’s Prescribing Information, refining recommended starting mealtime doses when adults switch from injected or pump-based ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mnkd/mannkind/news/the-bull-case-for-mannkind-mnkd-could-change-following-fda-b\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4584","symbol_name":"避孕概念","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mnkd/mannkind/news/the-bull-case-for-mannkind-mnkd-could-change-following-fda-b","article_id":"2607078110","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mnkd/mannkind/news/the-bull-case-for-mannkind-mnkd-could-change-following-fda-b","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2607078110","pubTimestamp":1769805430,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"MannKind Corporation recently received FDA approval for an update to Afrezza’s Prescribing Information, refining recommended starting mealtime doses when adults switch from injected or pump-based insulin to the inhaled therapy, based on new modeling and clinical data.\nThis label change is significant because clearer conversion guidance may influence how comfortably physicians transition suitable diabetes patients to Afrezza’s ultra rapid-acting inhaled insulin option, while keeping its known...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4584":"避孕概念","BK4139":"生物科技","MNKD":"曼恩凯德生物医疗"},"translate_title":"FDA支持的Afrezza剂量标签更新后，MannKind(MNKD)的牛市案例可能会发生变化","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MNKD":1.5},"content_text":"MannKind Corporation recently received FDA approval for an update to Afrezza’s Prescribing Information, refining recommended starting mealtime doses when adults switch from injected or pump-based insulin to the inhaled therapy, based on new modeling and clinical data. This label change is significant because clearer conversion guidance may influence how comfortably physicians transition suitable diabetes patients to Afrezza’s ultra rapid-acting inhaled insulin option, while keeping its known pulmonary safety profile front and center. We’ll now examine how this FDA-backed dosing update, aimed at easing transitions from injected to inhaled insulin, shapes MannKind’s investment narrative. Uncover the next big thing with financially sound penny stocks that balance risk and reward.AdvertisementWhat Is MannKind's Investment Narrative?For MannKind, the big-picture thesis still hinges on Afrezza gaining broader adoption while the company manages its debt load and advances its Technosphere-based and partnered products. The new FDA-approved Afrezza label, with clearer dose conversion from injected and pump insulin, neatly supports that story by reducing one practical barrier for prescribers, but on its own it may not transform near-term revenue without a visible inflection in new starts. Short-term catalysts remain centered on Afrezza uptake trends, Tyvaso DPI and FUROSCIX progress, and how MannKind uses its Blackstone financing capacity. At the same time, investors have to weigh clinical and pulmonary safety considerations, high leverage, a rich earnings multiple relative to many biotechs, and mixed share-price performance despite improving profitability. This label update fits more as a constructive increment than a reset of the risk‑reward profile. However, one key clinical and balance sheet risk could still surprise shareholders.  \nDespite retreating, MannKind's shares might still be trading above their fair value and there could be some more downside. Discover how much.Exploring Other PerspectivesMNKD 1-Year Stock Price Chart Four fair value estimates from the Simply Wall St Community span roughly US$7.42 to almost US$22.93 per share, underscoring how differently individual investors view MannKind’s potential. You are weighing those dispersed opinions against real uncertainties around Afrezza’s commercial traction, pulmonary safety monitoring requirements and the company’s sizeable debt, all of which could influence how much of that perceived upside is actually realised. Taken together, these contrasting viewpoints highlight why it can be useful to examine several independent assessments before forming your own view on MannKind’s prospects.Explore 4 other fair value estimates on MannKind - why the stock might be worth over 3x more than the current price!Build Your Own MannKind NarrativeDisagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.A great starting point for your MannKind research is our analysis highlighting 4 key rewards and 3 important warning signs that could impact your investment decision.Our free MannKind research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate MannKind's overall financial health at a glance.Ready For A Different Approach?Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:AI is about to change healthcare. These 111 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.Find companies with promising cash flow potential yet trading below their fair value.The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}